Renewal Bio

Ownership

Private

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Cell therapyregenerative medicinetissue engineering

Renewal Bio General Information

The company is developing novel cell replacement therapy solutions for human regenerative medicine and fertility. They have published research on ex utero mouse embryogenesis and synthetic embryos generated from mouse naïve ESCs, as well as complete human day 14 post-implantation embryo models from naïve ES cells.

Contact Information

Website

https://www.renewal.bio/

Primary Industry

Biotech

Corporate Office

Nes Ziona, Central District
Israel

Drug Pipeline

No pipeline data available

For full access to Renewal Bio's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Renewal Bio Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Renewal Bio's complete valuation and funding history, request access »